Low
₹1,420.40
High
₹1,460.00
| Previous Close | ₹1,436.90 |
|---|---|
| Day's Range | ₹1,420.40 - ₹1,460.00 |
| Open | ₹1,449.90 |
| 52 Week Range | ₹819.00 - ₹1,574.00 |
| Volume | 1,43,100 |
| Market Cap | ₹0.02 |
| Previous Close | ₹1,446.90 |
|---|---|
| Day's Range | ₹1,421.00 - ₹1,456.60 |
| Open | ₹1,438.05 |
| 52 Week Range | ₹830.00 - ₹1,573.00 |
| Volume | 8,293 |
| Market Cap | ₹0.02 |
| Trade Value ( ₹ in Lacs) | 2,056.20 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.34 |
| Price/Earning (TTM) | 26.62 |
| TTM EPS (₹) | 54.47 |
| P/E Ratio | 21.18 |
| Book Value(₹) | 4.91 |
| PAT Margin (%) | 21.89 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 24.61 |
| Trade Value ( ₹ in Lacs) | 119.99 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.34 |
| Price/Earning (TTM) | 26.62 |
| TTM EPS (₹) | 54.47 |
| P/E Ratio | 21.18 |
| Book Value(₹) | 4.91 |
| PAT Margin (%) | 21.89 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 24.61 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 5879.8 | 23868.84 |
| Expenses | N/A | N/A |
| PBT | 1741.37 | 6541.31 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 1300.26 | 4856.27 |
| Founded | 2011 |
|---|---|
| Managing Director | Yasir Rawjee |
| NSE Symbol | ALIVUS |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,56,593.44 | 1,885.10 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,96,740.78 | 11,200.00 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,75,577.80 | 4,698.80 | 3,672.30 - 3,672.30 |
| Lenskart Solutions Ltd. | 1,28,977.63 | 737.00 | 0.00 - 0.00 |
| Apollo Hospitals Enterprise Ltd. | 1,25,736.81 | 9,190.05 | 6,696.50 - 6,696.50 |
| Laurus Labs Ltd. | 1,24,379.87 | 2,295.00 | 917.95 - 917.95 |
| Zydus Lifesciences Ltd. | 1,19,700.46 | 1,195.05 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,16,770.96 | 1,390.50 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,14,396.95 | 1,414.95 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,08,640.97 | 2,660.00 | 1,909.70 - 1,909.70 |
No Records Found
NATCO Pharma has informed that it enclosed the Press Release under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the receipt of Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage Formulations (FDF) Unit.
Pursuant to Regulation 30 of SEBI LODR, Wanbury has informed that company’s API manufacturing facility at Tanuku, Andhra Pradesh, has successfully completed a three-day cGMP inspection conducted by the Ministry of Food and Drug Safety (MFDS), Republic of Korea, with zero observations. The inspection was conducted by two senior inspectors from South Korea’s MFDS, a leading international pharmaceutical regulatory authority, covering the facility’s compliance with applicable Good Manufacturing Practices (cGMP) standards. This achievement follows the successful completion of a South Korea MFDS cGMP inspection at the Company’s Patalganga manufacturing facility in April 2026, which was also concluded with zero observations. These consecutive achievements reflect Wanbury Limited’s strong commitment to quality, regulatory compliance and operational excellence. The Company remains focused on continuously strengthening its quality systems and enhancing manufacturing standards in line with evolving international regulatory requirements and global cGMP expectations.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Alivus Life Sciences Ltd. is ₹1,436.90 as of 2026-11-20.
The market capitalisation of Alivus Life Sciences Ltd. is ₹17,828.41 as of 2026-11-19.
The 1-year return of Alivus Life Sciences Ltd. is 529.15% as of 2026-11-20.
The P/E ratio of Alivus Life Sciences Ltd. is 21.18 as of 2026-11-20.
The 52-week high and low of Alivus Life Sciences Ltd. are ₹1,574.00 and ₹819.00, respectively, as of 2026-11-20.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.